甘李药业：就巴西甘精胰岛素等项目签订不低于30亿元供应框架协议

Group 1 - The company has signed a Technology Transfer and Supply Agreement with Fundação Oswaldo Cruz-Bio-Manguinhos (FZ) and BIOMM for the Brazil Production Development Partnership (PDP) project, with a total contract value expected to be no less than RMB 300,000 million (including tax) [1] - The PDP project aims to strengthen the public health system in Brazil and ensure a stable supply of essential medicines by transferring advanced product technology from multinational pharmaceutical companies to local production [1][2] - The company's proposal for the PDP project has been approved by the Brazilian government, establishing it as the only approved plan for the project [2] Group 2 - The contract specifies that the company will transfer the technology for insulin glargine to FZ and supply insulin glargine injection and raw materials to BIOMM, which will in turn transfer the filling technology to FZ [2] - FZ, as the technology recipient and final purchaser, commits to purchasing the agreed quantities and prices from BIOMM over the next 10 years [2]